                         SEQUENCE LISTING

<110>  Nuntius Therapeutics Ltd
 
<120>  Nucleic Acid Delivery

<130>  008161242

<140>  PCT/EP2022/052145
<141>  2022-01-28

<150>  GB2101301.6
<151>  2021-01-29

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Muscle targeting motif

<400>  1

Gly Ala Ala Ser Ser Leu Asn Ile Ala 
1               5                   


<210>  2
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa= 6-aminohexanoic acid

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa= 6-aminohexanoic acid

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Ala= beta-alanine

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  Xaa= 6-aminohexanoic acid

<220>
<221>  MOD_RES
<222>  (12)..(12)
<223>  Ala= beta-alanine

<220>
<221>  MOD_RES
<222>  (14)..(14)
<223>  Xaa= 6-aminohexanoic acid

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Ala= beta-alanine

<400>  2

Xaa Arg Xaa Arg Arg Ala Arg Arg Xaa Arg Arg Ala Arg Xaa Ala 
1               5                   10                  15  


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Muscle targeting peptide

<400>  3

Ala Ser Ser Leu Ile Asn Ala 
1               5           


